Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, creating a fully integrated global biosimilars leader. Amneal LLC paid $375 million in cash and issued approximately 28.94 million shares of Class A common stock to the sellers. The transaction includes up to $350 million in contingent regulatory milestone payments and potential royalties based on gross profit hurdles. To fund the acquisition, Amneal LLC secured a $350 million incremental term loan under an amendment to its existing credit agreement. This strategic combination integrates Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial scale, positioning the company to capitalize on upcoming biologic loss-of-exclusivity events. Amneal Pharmaceuticals is a diversified global biopharmaceutical company focused on affordable generic, specialty, and biosimilar medicines.

On August 3, 2026, Amneal Pharmaceuticals LLC entered into Amendment No. 3 to its Term Loan Credit Agreement with JPMorgan Chase Bank and other lenders. The amendment converted existing term loans into new loans totaling $2.039 billion and incurred an additional $45.2 million in new debt. Proceeds from the new loan were used to prepay non-converted existing loans at par. The repricing reduces interest rate margins by 50 basis points, resulting in estimated annualized cash interest savings of approximately $12 million. The maturity date remains August 1, 2032. Amneal Pharmaceuticals operates in the pharmaceutical industry, specializing in generic and specialty medications.

Amneal Pharmaceuticals held a special meeting on July 31, 2026, where stockholders approved the acquisition of 100% of Kashiv BioSciences from its equityholders. The transaction involves issuing 28,942,108 shares of Class A common stock to the sellers and is expected to close in the second half of 2026, pending remaining conditions including regulatory approvals. Amneal Pharmaceuticals operates in the pharmaceutical industry, specializing in generic and specialty drugs.

Amneal Pharmaceuticals reported second quarter 2026 results with net revenue of $796 million, a 10% increase year-over-year. GAAP net income rose 157% to $58 million, or $0.18 diluted EPS, while adjusted EBITDA increased 12% to $206 million and adjusted diluted EPS reached $0.30. The company raised its full-year 2026 guidance for net revenue to $3.10–$3.20 billion and adjusted EBITDA to $750–$780 million. Additionally, Amneal announced a debt repricing of its $2.084 billion Term Loan B in July 2026, reducing the interest spread by 50 basis points to generate approximately $12 million in annual savings. The firm operates as a diversified global biopharmaceutical company specializing in complex generics, specialty medicines, and biosimilars.